Detalhe da pesquisa
1.
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.
Nature
; 545(7654): 360-364, 2017 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28489825
2.
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Breast Cancer Res Treat
; 184(1): 53-62, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32803633
3.
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Invest New Drugs
; 38(3): 821-830, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31338636
4.
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Invest New Drugs
; 37(3): 461-472, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30229512
5.
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Invest New Drugs
; 37(4): 722-730, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30591982
6.
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol
; 154(2): 294-301, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31174889
7.
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.
Proc Natl Acad Sci U S A
; 109(29): 11717-22, 2012 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22753465
8.
Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.
Breast Cancer Res Treat
; 135(3): 913-22, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22941572
9.
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Clin Cancer Res
; 28(5): 882-892, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34844977
10.
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Blood
; 112(8): 3434-43, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18474728
11.
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Clin Cancer Res
; 26(20): 5348-5357, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32694153
12.
Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs.
PLoS One
; 15(3): e0229445, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32160239
13.
Heterogeneous activation of the TGFbeta pathway in glioblastomas identified by gene expression-based classification using TGFbeta-responsive genes.
J Transl Med
; 7: 12, 2009 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-19192267
14.
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Cancer Med
; 8(11): 5148-5157, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31347292
15.
p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation.
J Pharmacol Exp Ther
; 324(3): 921-9, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18056868
16.
Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.
Pharmacology
; 81(3): 204-20, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18176091
17.
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.
Target Oncol
; 13(1): 89-98, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29188408
18.
B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells.
Endocrinology
; 148(8): 3722-9, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17478552
19.
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Neuro Oncol
; 9(3): 259-70, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17522330
20.
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Anticancer Res
; 27(6B): 4149-57, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18229422